Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

Author:

Tap William D.12,Wagner Andrew J.3,Schöffski Patrick4,Martin-Broto Javier5,Krarup-Hansen Anders6,Ganjoo Kristen N.7,Yen Chueh-Chuan89,Abdul Razak Albiruni R.10,Spira Alexander11,Kawai Akira12,Le Cesne Axel13,Van Tine Brian A.14,Naito Yoichi15,Park Se Hoon16,Fedenko Alexander17,Pápai Zsuzsanna18,Soldatenkova Victoria19,Shahir Ashwin20,Mo Gary19,Wright Jennifer19,Jones Robin L.21,

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Department of Medicine, Weill Cornell Medical College, New York, New York

3. Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

4. University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium

5. Medical Oncology Department in University Hospital Virgen del Rocio and Institute of Biomedicine of Sevilla (IBIS) (HUVR, CSIC, University of Sevilla), Sevilla, Spain

6. University of Copenhagen, Copenhagen, Denmark

7. Stanford University, Stanford, California

8. Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

9. National Yang-Ming University School of Medicine, Taipei, Taiwan

10. Princess Margaret Cancer Center, Toronto, Ontario, Canada

11. Virginia Cancer Specialists, Fairfax

12. National Cancer Center Hospital, Tokyo, Japan

13. Institut Gustave Roussy, Villejuif, France

14. Department of Internal Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri

15. National Cancer Center Hospital East, Kashiwa, Japan

16. Sungkyunkwan University Samsung Medical Center, Seoul, Republic of Korea

17. Blokhin Cancer Research Center, Moscow, Russian Federation

18. Magyar Honvedseg Eu Kp, Budapest, Hungary

19. Eli Lilly and Company, Indianapolis, Indiana

20. Eli Lilly and Company, Windlesham, United Kingdom

21. Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom

Publisher

American Medical Association (AMA)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3